Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: An Update On Investigation, Diagnosis And Treatment

A. Bibby, S. Tsim, N. Kanellakis, Hannah L. Ball, D. Talbot, K. Blyth, N. Maskell, I. Psallidas
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years. This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised. This article on mesothelioma describes pathogenesis, symptoms, diagnostic approaches and treatment options http://ow.ly/cjkb305aQGz
This paper references
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1016/S1010-7940(03)00609-2
Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?
D. Stewart (2003)
10.1097/MCP.0000000000000258
Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies
A. Bibby (2016)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1136/thx.2008.100545
Thoracic ultrasound in the diagnosis of malignant pleural effusion
N. R. Qureshi (2008)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1002/emmm.201100176
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
D. Torti (2011)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.lungcan.2009.07.016
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
R. Hassan (2010)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1158/1538-7445.AM2015-CT103
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
E. Alley (2015)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Kenneth Lin (2011)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1016/J.YPDI.2011.01.018
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
L. Tanoue (2011)
10.1136/thoraxjnl-2015-207770.25
S19 Interventions for the management of malignant pleural effusions
A. Clive (2015)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Thorac Dis 2013; 5: E254–E307
J mesothelioma (2013)
10.1148/radiol.12110872
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1200/JCO.20.5.1335
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
M. Socinski (2002)
10.1158/2326-6066.CIR-13-0170
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
G. Beatty (2013)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1046/j.1440-1843.2000.00235.x
A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions
K. Ong (2000)
10.1177/106002809302700627
Bleomycin versus Doxycycline: A Patient-Oriented Approach to Pleurodesis
D. K. Fuller (1993)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Talc pleurodesis. Prospective and randomized study. Clinical follow-up
N Manes (2000)
10.1148/radiol.14132111
Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.
J. Coolen (2015)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1136/bmjopen-2016-012092
What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK
A. Bibby (2016)
10.1378/CHEST.127.3.909
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
C. Dresler (2005)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1136/oem.54.6.403
Routes of asbestos exposure and the development of mesothelioma in an English region.
D. Howel (1997)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1158/2326-6066.CIR-15-0064
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
L. Emens (2015)
10.3322/canjclin.52.2.72
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
A. Inui (2002)
152: Suppl 6, S64–S71
F López-Ríos (1999)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
Prostate-specific antigen-based screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Agency for Research Health and Quality
K Lin (2011)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
10.1186/1745-6215-15-367
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
Samal Gunatilake (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
of Thoracic Surgeons for management of Malignant Pleural Mesothelioma
A. Scherpereel (2009)
10.2307/3580117
The german thorotrast study: recent results and assessment of risks.
G. van Kaick (1999)
10.12968/hmed.2015.76.7.384
Medical and oncological management of malignant mesothelioma.
A. Bibby (2015)
10.1136/thx.2010.136978
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
C. Hooper (2010)
Antibody Pembrolizumab in Patients with Malignant Mesothelioma
(2015)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/S1040-1741(08)70174-X
Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module
N. Hanna (2006)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
pleural mesothelioma in the National Lung Cancer Audit in England and Wales
M Carbone (2015)
10.1378/CHEST.106.2.342
Pleurodesis using talc slurry.
L. Kennedy (1994)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1378/CHEST.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1016/S0140-6736(15)01311-2
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1371/journal.pone.0046091
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
The experience of mesothelioma in northern England.
H. Clayson (2007)
10.1200/JCO.2004.09.147
Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
A. Nowak (2004)
10.1093/ANNONC/MDV514.06
16TiPA phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study
L. Calabrò (2015)
Prostate-specific antigen-based screening for prostate cancer: an evidence update for the US Preventive Services Task Force
K Lin (2011)
A phase II trial of surgical resection and adjuvant highdose hemithoracic radiation for malignant pleural mesothelioma
VW Rusch (2001)
10.7326/0003-4819-120-1-199401010-00010
Chemical Pleurodesis for Malignant Pleural Effusions
P. Walker-Renard (1994)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Department of Health. Mesothelioma Service Framework. Dept of Health Lung Cancer and Mesothelioma Advisory Group
(2007)
Pilot and feasibility trial of immuno-gene therapy of malignant mesothelioma using intrapleural dlivery of adenovirus-interferon-α combined with chemotherapy
DH Sterman (2016)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1002/14651858.CD010529.pub2
Interventions for the management of malignant pleural effusions: a network meta-analysis.
A. Clive (2016)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
HL Kindler (2015)
multidisciplinary pain management group in a palliative care unit
AH Lebovits (2005)
MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2). NCT02040272
E Lim
10.1016/J.HOC.2005.09.003
Mesothelioma from the patient's perspective.
H. Clayson (2005)
10.1200/JCO.2015.33.15_SUPPL.7565
Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).
R. Hassan (2015)
10.1179/096992603322731143
Suffering in mesothelioma: concepts and contexts
H. Clayson (2003)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
British Thoracic Society Standards of Care Committee
S. Blumenthal (2014)
10.1017/S1478951505050078
Challenging the representations of cancer pain: experiences of a multidisciplinary pain management group in a palliative care unit.
E. Chapman (2005)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
Adaptation in Health and Illness, Sydney
N Hughes (2004)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1038/nrc2068
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
M. Carbone (2007)
Audit in England and Wales
M Carbone (2015)
10.1002/pon.3162
‘It's all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma
A. Arber (2013)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
10.1001/jama.2015.16840
Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.
N. Rahman (2015)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1136/thx.2010.136994
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Roberts (2010)
10.1177/028418518602700507
Computed Tomography of Pleural Lesions with Special Reference to the Mediastinal Pleura
O. Salonen (1986)
10.1056/NEJMc1509660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi (2015)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1001/jama.2012.5543
Treatment options for malignant pleural effusions: patient preference does matter.
N. Maskell (2012)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1016/S0084-3873(11)00245-8
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Raza (2011)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.1017/erm.2012.6
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1016/j.lungcan.2015.03.005
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
P. Beckett (2015)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.12968/IJPN.2008.14.2.28597
The lived experience of patients with pleural mesothelioma.
Nicola Hughes (2008)
10.1136/thx.45.2.81
Management of malignant pleural effusions.
M. Tattersall (1990)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1016/S0140-6736(04)17102-X
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids
F. Lopez-Rios (2004)
10.1002/cncr.28875
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
10.1016/j.ejrad.2008.02.004
Malignant pleural mesothelioma: computed tomography and correlation with histology.
J. Seely (2009)
10.1378/chest.14-0820
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
J. M. Porcel (2015)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1016/j.jtcvs.2015.10.036
Pleurectomy decortication for mesothelioma: The procedure of choice when possible.
R. Flores (2016)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
The mesothelioma journey: developing strategies to meet the needs of people with mesothelioma, their family carers and health professionals involved in their care
R Hawley (2004)
10.1136/thx.2010.137026
Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010
T. Havelock (2010)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1177/1753465815570307
Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion
W. Keeratichananont (2015)
antigen 125
R Hassan (2014)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/j.jtcvs.2015.10.054
The mesothelioma surgery shift.
R. Flores (2016)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1001/jama.2012.5535
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
Simian virus 40-like DNA sequences in human pleural mesothelioma.
M. Carbone (1994)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1159/000056290
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2)
E. Lim (2016)
10.1158/1078-0432.CCR-15-2133
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma
D Torti (2015)
10.1093/annonc/mdu342.27
1074TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TREMELIMUMAB FOR SECOND-LINE AND THIRD-LINE TREATMENT OF UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA.
A. Scherpereel (2014)
10.1378/CHEST.118.3.604
MRI and CT in the differential diagnosis of pleural disease.
J. Hierholzer (2000)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/S0140-6736(11)60993-8
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (2011)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.22605/RRH1183
A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia.
S. Lee (2009)
10.1200/JCO.2014.32.15_SUPPL.TPS7609
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.
M. Maio (2014)
10.1016/j.acra.2013.09.015
Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
G. Treglia (2014)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
10.1002/AJIM.4700040306
Exposure to asbestos: psychological responses of mesothelioma patients.
A. Lebovits (1983)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1016/J.EJCTS.2006.01.015
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2006)
SV40 induces mesotheliomas in hamsters.
C. Cicala (1993)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP 1 , NF 2 , CDKN 2 A , and CUL 1 in Malignant Pleural Mesothelioma
Guangwu Guo (2014)



This paper is referenced by
10.21873/invivo.11360
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma
Y. Negi (2018)
10.21873/anticanres.13530
2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth
I. Gerogianni (2019)
Asbestos , Mesothelioma and Lung Cancer : A Comment
S. Jargin (2017)
10.1053/j.seminoncol.2019.06.001
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
10.1159/000486578
Management and Survival of Pleural Mesothelioma: A Record Linkage Study
G. Carioli (2018)
10.21037/jtd.2017.10.19
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
10.1007/978-981-13-1217-5_62
Diagnosis of Malignant Pleural Mesothelioma Using KNN
M. Kaur (2019)
10.1016/j.lungcan.2018.10.009
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
M. Rosskamp (2018)
10.3390/cells9041019
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
Y. Nishinaga (2020)
10.5455/aim.2018.26.185-189
Comparison of Efficiency of Pleurodesis Between Video Assisted Thoracoscopic Surgery (VATS) and Standard Thoracostomy
A. Alihodžić-Pašalić (2018)
10.3390/ijerph17031110
Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review
Zehra Nur Töreyin (2020)
10.1073/pnas.1818865116
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
Tania Villanova (2019)
10.1007/978-3-030-04155-7_9
Infectious Agents Associated with Mesothelioma
N. S. Lam (2019)
10.18632/oncotarget.25237
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma
Stefania Augeri (2018)
10.21873/anticanres.13719
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
10.1080/19338244.2018.1467873
A review of the cohorts with environmental and occupational mineral fiber exposure
S. Metintaş (2019)
10.18632/oncotarget.20409
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
Kimberly A. Birnie (2017)
10.3390/medicina55080490
Malignant Pleural Effusion and Its Current Management: A Review
Kristijan Skok (2019)
10.7759/cureus.2749
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor
C. Salazar (2018)
10.1016/j.trsl.2017.04.004
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
M. Zeltsman (2017)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.1007/978-3-030-33832-9_20
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies
L. Santarelli (2020)
10.1038/s41598-017-19004-3
Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma
E. Gamazon (2017)
10.1177/0004563217741145
Biomarkers in mesothelioma
D. Arnold (2018)
10.1080/15384047.2018.1472193
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma
Jiale Wang (2018)
10.1159/000494500
Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study
M. A. Mitchell (2018)
10.1007/s13665-019-0224-9
Malignant Pleural Mesothelioma: an Update for Pulmonologists
C. Sidhu (2019)
10.1016/j.lungcan.2018.01.001
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
10.21037/jtd.2017.10.09
Clinical diagnosis of malignant pleural mesothelioma.
A. Bianco (2018)
10.3390/cancers11101502
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
D. Xu (2019)
10.1136/thoraxjnl-2020-215027
Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
N. Kanellakis (2020)
10.1007/978-3-030-27233-3_8
Primary Tumors of the Pleura
R. Ledda (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar